Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin

J Cardiovasc Electrophysiol. 2020 Aug;31(8):1904-1907. doi: 10.1111/jce.14594. Epub 2020 Jun 20.
No abstract available

Keywords: COVID-19; azithromycin; hydroxychloroquine; long QT syndrome; torsades de pointes.

Publication types

  • Comment

MeSH terms

  • Azithromycin / adverse effects
  • COVID-19*
  • Humans
  • Hydroxychloroquine / adverse effects
  • Incidence
  • Long QT Syndrome* / epidemiology
  • Pandemics
  • Patients
  • SARS-CoV-2
  • Torsades de Pointes*

Substances

  • Hydroxychloroquine
  • Azithromycin